Cross Border
-
Tencent: Investing machine
There's a purpose behind Tencent's frenzy of dealmaking: Keep users coming back to its platform
-
First show: Debutants on Fab 50 list
These companies are joining the elite list for the first time after outperforming their rivals
-
Opportunity zones: Break and build
The never-told story of how an unlikely group of billionaires and politicians quietly passed a law that revolutionises investment in struggling regions—and offers one of the greatest tax-avoidance opportunities in American history
-
Avenue Supermarts: Shopping sensation
Thanks to its "everyday low prices" model, the Indian retailer storms into the Fab 50
-
China dominates Asia's Fab 50 list
India has the second highest number of companies on the list after China
-
Maybe You Don't Need a Colonoscopy
Exact Sciences has a pretty good test for cancer. Gastroenterologists are unenthusiastic
-
ByteDance to the music
The super-unicorn's Douyin video site is cutting in on WeChat's hold on Chinese youth
-
Cambodia embraces booming Chinese investment
As mainland money and visitors pour into Cambodia, China backs two new airports. Too bad about the French company that had an exclusive concession
-
Bilibili: Show me the money
Chinese millennials are flocking to the anime and gaming site. But can it make a profit?
-
The world's highest-paid entertainers
The stars on Forbes's Celebrity 100 ranking earned a combined $6.3 billion over the past 12 months, up 22 percent from last year
-
Regeneron's billionaire founder fights for responsible pricing. But look who's talking
Leonard Schleifer condemns greed at other drug firms. But what about the $37,000 price tag on his eczema drug?